Formulations of apremilast

Provided herein are oral dosage forms comprising (a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and (b) a coating layer disposed on...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	INGRAM, KAZDEN, CALDWELL, WILLIAM BRETT, VILES, ALISON, HOSTETLER, CHRISTI, BENNETTE, NATHAN, KYBURZ, KYLE, KING, DORY
Format:	Patent
Sprache:	chi ; eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	INGRAM, KAZDEN CALDWELL, WILLIAM BRETT VILES, ALISON HOSTETLER, CHRISTI BENNETTE, NATHAN KYBURZ, KYLE KING, DORY
description	Provided herein are oral dosage forms comprising (a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and (b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_TW202313006A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>TW202313006A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_TW202313006A3</originalsourceid><addsrcrecordid>eNrjZJByyy_KLc1JLMnMzytWyE9TSCwoSs3NzEksLuFhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfEh4UYGRsaGxgYGZo7GxKgBAGqYI2E</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Formulations of apremilast</title><source>esp@cenet</source><creator>INGRAM, KAZDEN ; CALDWELL, WILLIAM BRETT ; VILES, ALISON ; HOSTETLER, CHRISTI ; BENNETTE, NATHAN ; KYBURZ, KYLE ; KING, DORY</creator><creatorcontrib>INGRAM, KAZDEN ; CALDWELL, WILLIAM BRETT ; VILES, ALISON ; HOSTETLER, CHRISTI ; BENNETTE, NATHAN ; KYBURZ, KYLE ; KING, DORY</creatorcontrib><description>Provided herein are oral dosage forms comprising (a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and (b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230401&DB=EPODOC&CC=TW&NR=202313006A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230401&DB=EPODOC&CC=TW&NR=202313006A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>INGRAM, KAZDEN</creatorcontrib><creatorcontrib>CALDWELL, WILLIAM BRETT</creatorcontrib><creatorcontrib>VILES, ALISON</creatorcontrib><creatorcontrib>HOSTETLER, CHRISTI</creatorcontrib><creatorcontrib>BENNETTE, NATHAN</creatorcontrib><creatorcontrib>KYBURZ, KYLE</creatorcontrib><creatorcontrib>KING, DORY</creatorcontrib><title>Formulations of apremilast</title><description>Provided herein are oral dosage forms comprising (a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and (b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJByyy_KLc1JLMnMzytWyE9TSCwoSs3NzEksLuFhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfEh4UYGRsaGxgYGZo7GxKgBAGqYI2E</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>INGRAM, KAZDEN</creator><creator>CALDWELL, WILLIAM BRETT</creator><creator>VILES, ALISON</creator><creator>HOSTETLER, CHRISTI</creator><creator>BENNETTE, NATHAN</creator><creator>KYBURZ, KYLE</creator><creator>KING, DORY</creator><scope>EVB</scope></search><sort><creationdate>20230401</creationdate><title>Formulations of apremilast</title><author>INGRAM, KAZDEN ; CALDWELL, WILLIAM BRETT ; VILES, ALISON ; HOSTETLER, CHRISTI ; BENNETTE, NATHAN ; KYBURZ, KYLE ; KING, DORY</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_TW202313006A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2023</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>INGRAM, KAZDEN</creatorcontrib><creatorcontrib>CALDWELL, WILLIAM BRETT</creatorcontrib><creatorcontrib>VILES, ALISON</creatorcontrib><creatorcontrib>HOSTETLER, CHRISTI</creatorcontrib><creatorcontrib>BENNETTE, NATHAN</creatorcontrib><creatorcontrib>KYBURZ, KYLE</creatorcontrib><creatorcontrib>KING, DORY</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>INGRAM, KAZDEN</au><au>CALDWELL, WILLIAM BRETT</au><au>VILES, ALISON</au><au>HOSTETLER, CHRISTI</au><au>BENNETTE, NATHAN</au><au>KYBURZ, KYLE</au><au>KING, DORY</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Formulations of apremilast</title><date>2023-04-01</date><risdate>2023</risdate><abstract>Provided herein are oral dosage forms comprising (a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and (b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	chi ; eng
recordid	cdi_epo_espacenet_TW202313006A
source	esp@cenet
subjects	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	Formulations of apremilast
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A35%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=INGRAM,%20KAZDEN&rft.date=2023-04-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ETW202313006A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true